MapLight Therapeutics, Inc. (MPLT) Ownership — Insider & Political Trading

MapLight Therapeutics, Inc. (MPLT) — Price $11.40 HealthcareBiotechnology — NASDAQ

Latest reported results:

Ownership and insider activity for MapLight Therapeutics, Inc. (MPLT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis.

Price

Price$11.40
Market Cap$484M
ExchangeNASDAQ
CountryUS

Balance Sheet (10y)

Year2022202320242025
Cash & Equivalents$27.7M$79.8M$38.3M$46.7M
Short-term Investments00$70.5M$258.4M
Receivables0000
Inventory0000
Total Current Assets$32.0M$83.6M$114.6M$324.7M
Property, Plant & Equipment$7.1M$6.6M$7.6M$6.6M
Goodwill0000
Intangible Assets0000
Total Assets$39.4M$91.4M$136.9M$479.5M
Accounts Payable00$1.9M0
Short-term Debt$348000$495000$778000$891000
Total Current Liabilities$12.6M$14.7M$15.9M$16.2M
Long-term Debt0000
Total Liabilities$18.5M$20.1M$21.7M$21.1M
Retained Earnings-$66.1M-$121.8M-$199.4M-$360.5M
Total Equity$20.9M$71.3M$115.2M$458.4M
Total Debt$6.3M$5.9M$6.6M$5.8M
Net Debt-$21.4M-$73.8M-$102.2M-$299.3M
Working Capital$19.4M$68.9M$98.7M$308.4M

Financial Health

Debt / Equity0.01
Current Ratio16.52
Piotroski F-Score3
Altman Z-Score20.51

Profitability

Return on Equity-35.16%
Return on Invested Capital-36.43%
Return on Assets-33.61%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%

Related companies: BRTX · DWTX · EDSA · ERNA · IMRN · LPCN · OSRH

Explore sector: Healthcare · Biotechnology

More sections of MPLT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks